CTXR
Citius Pharmaceuticals, Inc.
$0.5600
-5.08%
$16.2M
No data for this timeframe.
Vol
Market Cap$16.2M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders5 funds
Inst. Value$203.9K
Inst. Activity2 buys / 1 sells
Reddit Sentiment58° Warm
SEC Reports6
Recent Activity
Jun 3, 2026
SEC
The SEC declared effective Citius Pharmaceuticals' S-3 shelf registration (File No. 333-296195) on June 2, 2026. This en
EFFECT — Impact 6/10
Jun 1, 2026
SEC
Citius Pharmaceuticals' subsidiary Citius Oncology presented Phase 1 data for LYMPHIR in combination with pembrolizumab
8-K — Impact 4/10
May 22, 2026
SEC
Citius Pharmaceuticals filed an S-3 registration statement to register 5,431,473 shares of common stock for resale by se
S-3 — Impact 6/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
60,838 shares ($47.3K)
Inst.
MORGAN STANLEY — DOUBLED
2,032 shares ($1.6K)
May 20, 2026
short_volume
Short Volume: CTXR — 60.5% short (0.4M / 0.6M)
Short: 358,236 | Exempt: 0 | TRF Vol: 592,549 | Short Ratio: 60.5% | Off-exchange volume (dark pool
Price Targets
$4.00
+614.3% upside
Strong Buy
Current $0.5600
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 11, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 | $-0.36 — $-0.36 | 55% YoY | 1 |
| Next Q | $-0.25 | $-0.25 — $-0.25 | -127% YoY | 1 |
| Current FY | $-1.87 ▼ -212.7% | $-1.87 — $-1.87 | 45% YoY | 1 |
| Next FY | $-0.81 ▼ -129.0% | $-0.81 — $-0.81 | 57% YoY | 1 |
Latest Reports
BEARISH
EFFECT
6/10
The SEC declared effective Citius Pharmaceuticals' S-3 shelf registration (File No. 333-296195) on June 2, 2026. This en
Jun 3, 2026
NEUTRAL
8-K
4/10
Citius Pharmaceuticals' subsidiary Citius Oncology presented Phase 1 data for LYMPHIR in combination with pembrolizumab
Jun 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $154.8K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $47.3K | DOUBLED |
| MORGAN STANLEY | $1.6K | DOUBLED |
| BANK OF AMERICA CORP | $238.00 | TRIM |
| WELLS FARGO & COMPANY/MN | $31.00 | — |
Reddit Sentiment
58°
Warm
Bearish
Neutral
Bullish
5 institutional holders with $203.9K total value (262,475 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 199,258 | $154.8K | 75.9% | DOUBLED +107.7% |
| 2 | TWO SIGMA INVESTMENTS, LP | 60,838 | $47.3K | 23.2% | DOUBLED +179.0% |
| 3 | MORGAN STANLEY | 2,032 | $1.6K | 0.8% | DOUBLED +399.3% |
| 4 | BANK OF AMERICA CORP /DE/ | 307 | $238.00 | 0.1% | TRIM -27.3% |
| 5 | WELLS FARGO & COMPANY/MN | 40 | $31.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 21,803 | 60,838 | +179.0% | $47.3K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 407 | 2,032 | +399.3% | $1.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 422 | 307 | -27.3% | $238.00 | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 80,103 | 166,390 | +107.7% | $206.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 192,927 | 25,913 | -86.6% | $32.1K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 12,874 | 21,803 | +69.4% | $27.0K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 60 | 407 | +578.3% | $504.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 67,215 | 192,927 | +187.0% | $306.8K | 2025-Q2 |
| VANGUARD GROUP INC | TRIM | 257,631 | 80,103 | -68.9% | $127.4K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 12,874 | — | $20.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 68 | 377 | +454.4% | $599.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 27,567 | 67,215 | +143.8% | $100.2K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 318 | 60 | -81.1% | $89.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 115,200 | 32,737 | -71.6% | $130.9K | 2024-Q4 |
| UBS Group AG | NEW | — | 27,567 | — | $110.3K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 76,073 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 115,200 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 76,073 | — | $38.1K | 2024-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 9,740 | 1,500 | -84.6% | $751.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 0 bullish, 5 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BEARISH
EFFECT
6/10
The SEC declared effective Citius Pharmaceuticals' S-3 shelf registration (File No. 333-296195) on J
Jun 3, 2026
NEUTRAL
8-K
4/10
Citius Pharmaceuticals' subsidiary Citius Oncology presented Phase 1 data for LYMPHIR in combination
Jun 1, 2026
BEARISH
S-3
6/10
Citius Pharmaceuticals filed an S-3 registration statement to register 5,431,473 shares of common st
May 22, 2026
BEARISH
8-K
6/10
Citius Pharmaceuticals reported Q2 fiscal 2026 revenue of $1.7M (vs $0 a year ago) from LYMPHIR sale
May 15, 2026
BEARISH
8-K
6/10
Citius Pharmaceuticals entered into a securities purchase agreement to raise $5 million through a re
Apr 24, 2026
BEARISH
424B5
6/10
Citius Pharmaceuticals is raising $5 million through a registered direct offering of 4.73 million co
Apr 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.00 mean target
+614.3% upside
Strong Buy (1.00)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.5600 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.36 | $-0.36 | 55.0% | — | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.25 | $-0.25 | $-0.25 | -127.3% | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-09-30 |
$-1.87 | $-1.87 | $-1.87 | 44.7% | -212.7% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-09-30 |
$-0.81 | $-0.81 | $-0.81 | 56.7% | -129.0% | 0↑ 1↓ | $0.1B | 152.3% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.360 | |
| 7d ago | $0.000 | -0.360 |
| 30d ago | $0.000 | -0.360 |
| 60d ago | $0.000 | -0.360 |
| 90d ago | $0.000 | -0.360 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 11, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
58°
Warm
Bearish
Neutral
Bullish
2 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$CTXR quietly loading near support – biotech catalyst play?
▲ 11
💬 6
⚡ 0.2
CTXR? I’ve bought 600 shares - let me know your opinions
▲ 2
💬 3
⚡ 0.0
May 20, 2026
short_volume
Short Volume: CTXR — 60.5% short (0.4M / 0.6M)
Short: 358,236 | Exempt: 0 | TRF Vol: 592,549 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CTXR — 61.6% short (0.8M / 1.3M)
Short: 771,690 | Exempt: 92,057 | TRF Vol: 1,252,993 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
CTXR Q2 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
CTXR Q2 2026 Earnings Scheduled — 2026-05-12
Apr 30, 2026
short_volume
Short Volume: CTXR — 55.3% short (0.6M / 1.0M)
Short: 555,741 | Exempt: 134,181 | TRF Vol: 1,004,607 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: CTXR — 56.8% short (0.4M / 0.7M)
Short: 382,619 | Exempt: 32,012 | TRF Vol: 673,359 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: CTXR — 67.6% short (0.9M / 1.3M)
Short: 850,329 | Exempt: 53,596 | TRF Vol: 1,257,993 | Short Ratio: 67.6% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: CTXR — 60.5% short (0.9M / 1.4M)
Short: 869,225 | Exempt: 67,195 | TRF Vol: 1,436,290 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: CTXR — 58.3% short (1.3M / 2.2M)
Short: 1,257,338 | Exempt: 39,382 | TRF Vol: 2,158,425 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: CTXR — 59.7% short (0.7M / 1.2M)
Short: 711,151 | Exempt: 478 | TRF Vol: 1,191,860 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)